[
    [
        {
            "time": "2018-04-01",
            "original_text": "Keytruda: Merck’s Immuno-Oncology Blockbuster Drug in 1Q18",
            "features": {
                "keywords": [
                    "Keytruda",
                    "Merck",
                    "Immuno-Oncology",
                    "Blockbuster"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Keytruda: Merck’s Immuno-Oncology Blockbuster Drug in 1Q18",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "Celgene’s Otezla Witnessed Solid Growth in 1Q18",
            "features": {
                "keywords": [
                    "Celgene",
                    "Otezla",
                    "Solid Growth"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Celgene’s Otezla Witnessed Solid Growth in 1Q18",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "Biogen’s Key Partnerships: Eisai, Pfizer, AbbVie, and Ionis",
            "features": {
                "keywords": [
                    "Biogen",
                    "Partnerships",
                    "Eisai",
                    "Pfizer",
                    "AbbVie",
                    "Ionis"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Biogen’s Key Partnerships: Eisai, Pfizer, AbbVie, and Ionis",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "Why Did Biogen and AbbVie Recall Zinbryta?",
            "features": {
                "keywords": [
                    "Biogen",
                    "AbbVie",
                    "Recall",
                    "Zinbryta"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Why Did Biogen and AbbVie Recall Zinbryta?",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "AbbVie to Present at the UBS Global Healthcare Conference",
            "features": {
                "keywords": [
                    "AbbVie",
                    "UBS",
                    "Global Healthcare Conference"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie to Present at the UBS Global Healthcare Conference",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "How Analysts View Allergan after Its 1Q18 Earnings",
            "features": {
                "keywords": [
                    "Allergan",
                    "Analysts",
                    "1Q18 Earnings"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "How Analysts View Allergan after Its 1Q18 Earnings",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]